Whole-genome sequencing analysis of clozapine-induced myocarditis

Running title: Genome analysis of clozapine-induced myocarditis

Ankita Narang¹, Paul Lacaze², Kathlyn J Ronaldson², John J McNeil², Mahesh Jayaram^{3,4}, Naveen Thomas^{3,4}, Rory Sellmer⁵, David Crockford⁵, Robert Stowe⁶, Steven C. Greenway^{7,8,9,10,11}, Christos Pantelis^{3,4}, Chad A Bousman^{1,5,9,12,13}

¹Department of Medical Genetics, University of Calgary, Calgary, AB, Canada.

²Department of Epidemiology and Preventive Medicine, Monash University, Melbourne, VIC, Australia

³Adult Mental Health Rehabilitation Unit, North Western Mental Health, Melbourne Health, Western Health, Sunshine Hospital, St Albans, VIC, Australia

⁴Melbourne Neuropsychiatry Centre, Department of Psychiatry, The University of Melbourne and Melbourne Health, Western Centre for Health & Education, St Albans, VIC, Australia

⁵Department of Psychiatry, University of Calgary, Calgary, AB, Canada

⁶Departments of Psychiatry and Neurology (Medicine), Neuropsychiatry Program, and Djavad Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, BC, Canada

⁷Department of Pediatrics, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

⁸Department of Biochemistry & Molecular Biology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

⁹Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

¹⁰Department of Cardiac Sciences, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

¹¹Libin Cardiovascular Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

¹²Department of Physiology & Pharmacology, University of Calgary, Calgary, AB, Canada.

¹³Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

Correspondence: Chad Bousman, Department of Medical Genetics, University of Calgary, 270 HMRB, 3330 Hospital Drive NW, Calgary, AB T2N 4N1, Canada. Tel: +1 403 210 7273; e-mail: chad.bousman@ucalgary.ca

ABSTRACT

One of the concerns limiting the use of clozapine in schizophrenia treatment is the risk of rare but potentially fatal myocarditis. Our previous genome-wide association study and human leucocyte antigen analyses identified putative loci associated with clozapine-induced myocarditis. However, the contribution of DNA variation in cytochrome P450 genes, copy number variants and rare deleterious variants have not been investigated. We explored these unexplored classes of DNA variation using whole-genome sequencing data from 25 cases with clozapine-induced myocarditis and 25 demographically-matched clozapine-tolerant control subjects. We identified 15 genes based on rare variant gene-burden analysis (*MLLT6*, *CADPS*, *TACC2*, *L3MBTL4*, *NPY*, *SLC25A21*, *PARVB*, *GPR179*, *ACAD9*, *NOL8*, *C5orf33*, *FAM127A*, *AFDN*, *SLC6A11*, *PXDN*) nominally associated ($p < 0.05$) with clozapine-induced myocarditis. Of these genes, 13 were expressed in human myocardial tissue. Although independent replication of these findings is required, our study provides preliminary insights into the potential role of rare genetic variants in susceptibility to clozapine-induced myocarditis.

55 INTRODUCTION

56 Clozapine initiation for patients suffering from treatment-resistant schizophrenia is recommended at
 57 the earliest possible opportunity by clinical guidelines,^{1, 2} and there is evidence for its superior efficacy
 58 in this difficult-to-treat population compared with other pharmacological treatments³. Regulatory
 59 requirements around serious adverse event monitoring have largely addressed the risk of undiagnosed
 60 agranulocytosis. However, there has been ongoing concern about a serious idiosyncratic adverse drug
 61 reaction (ADR) involving inflammation of the myocardium.

62 In 1999, Kilian and colleagues⁴ reported the rate of myocarditis (both fatal and non-fatal) as 1.9
 63 per 1000 patients starting clozapine. However, more recent projections suggest rates as high as 3% in
 64 the context of systematic monitoring, with fatality rates ranging from 7% to 75%⁵. Despite these
 65 alarming rates, our current ability to identify those at greatest risk for clozapine-induced myocarditis is
 66 inadequate. This uncertainty has led to reduced clozapine prescription and arguably poorer patient
 67 outcomes. Although research to uncover risk factors has identified a few clinical markers^{6,7}, these
 68 factors do not account for all the risk. As such, identification of additional markers is needed to reduce
 69 or prevent fatalities and morbidity resulting from clozapine-induced myocarditis, potentially
 70 facilitating expanded and safer use of this highly effective medication.

71 Genomic analysis is a promising and largely unexplored approach for identifying those at risk
 72 of idiosyncratic ADRs. In fact, our recent genome-wide association study (GWAS) and human
 73 leucocyte antigen (HLA) analyses of clozapine-induced myocarditis identified four independent loci
 74 (*SIX3*, *EFHC1*, *ADAM7*, and *GNAI5*) suggestive of increased myocarditis risk ($P < 1 \times 10^{-6}$), with
 75 odds ratios ranging from 5.5 to 13.7. We also found that the HLA-C*07:01 allele was associated with
 76 2.89-fold (95% CI: 1.11–7.53) greater odds of clozapine-induced myocarditis⁸. To build on these
 77 promising findings, we undertook the first whole-genome sequencing study to examine different
 78 classes of DNA variation not measured in our previous genetic study, including rare deleterious coding
 79 variants, copy number variants, and candidate variation in pharmacogenes associated with clozapine
 80 metabolism. Herein, we report our results among a cohort of individuals with and without a history of
 81 clozapine-induced myocarditis, in collaboration with members of the Pharmacogenomics of
 82 Clozapine-Induced Myocarditis (PROCLAIM) Consortium⁹.

83
 84
 85

86

87 **METHODS**

88 **Study Participants**

89 Participants with (n = 25) and without (n = 25) a history of clozapine-induced myocarditis were
 90 recruited by investigators affiliated with the PROCLAIM Consortium at the University of Calgary,
 91 University of Melbourne, and Monash University. For this study, we included 34 participants (19 cases
 92 and 19 controls) included in our previous GWAS study⁸. For each recruited case of clozapine-induced
 93 myocarditis, an age ($\pm$ 5 years), sex, and ancestry-matched clozapine-tolerant control was recruited
 94 from the same site. Genetic ancestry of controls and cases was further assessed by principal component
 95 analysis using the smartpca module of the EIGENSOFT package (Supplementary Figure S1).
 96 Individuals were eligible for inclusion into the study if they: (a) were aged 18 to 65 years, (b) had a
 97 clinical diagnosis of a schizophrenia-spectrum disorder, (c) had accessible medical records, and (d) had
 98 a history of clozapine therapy. For cases, an additional inclusion criterion was a history of myocarditis
 99 evidenced by abnormal troponin I/T levels (>2 times upper limit of normal) or signs of left ventricular
 100 dysfunction with or without elevated C-reactive protein (CRP) levels ($>100\text{mg/L}$) during the first 30
 101 days of clozapine therapy, which aligns with current monitoring guidelines¹⁰. An additional inclusion
 102 criterion for clozapine-tolerant controls was evidence of clozapine therapy for a minimum of 45 days
 103 with no documented history or clinical suspicion of myocarditis. The present study was approved by
 104 the Melbourne Health Human Research Ethics Committee and University of Calgary Conjoint Health
 105 and Research Ethics Board. The study also complied with the Declaration of Helsinki and its
 106 subsequent revisions. All participants or next of kin provided written informed consent prior to
 107 participation.

108

109 **Whole genome sequencing**

110 Genomic DNA (750 – 1000 ng, A_{260}/A_{280} ratio > 1.8) was isolated from whole blood samples using
 111 standard procedures and shipped to the Centre for Applied Genomics at the Hospital for Sick Children
 112 (Toronto, Canada) for library preparation and sequencing. Libraries were prepared for all samples
 113 using the Illumina TruSeq PCR-free DNA library preparation kit. Each library was subjected to 150
 114 base, paired end sequencing on three lanes of the Illumina HiSeqX.

115 The Illumina DRAGEN (version 07.021.382.3.4.9, Dynamic Read Analysis for GENomics)
 116 Bio-IT platform was used for aligning reads to the human genome (reference build hg19). After

alignment, sorting and duplicate marking was performed to generate aligned BAM files. Next, sample-wise gVCF files were generated using DRAGEN's haplotype calling algorithm and then these files were run through the joint calling algorithm to generate a joint VCF file. dbSNP (v150) was used to annotate variants. The jointly called VCF file was further recalibrated using the Variant Quality Score Recalibration (VQSR) algorithm to produce a high-quality variant dataset. The VQSR model was trained for single nucleotide polymorphisms (SNPs) and insertion/deletions (indels) using high quality variant data from different resources (see Supplementary Methods for more details). For SNPs, the VQSR model was trained using data from HapMap3.3, 1000 Genomes Project (Phase 1 SNP sites and Omni 2.5 M SNP array) and dbSNP (v150), with a sensitivity threshold of 99.5%. For indels, the VQSR was trained using data in the 1000 Genomes Project (gold standard sites) and Illumina Platinum sites, with a sensitivity threshold of 99.0%. Only "PASS" calls were annotated using ANNOVAR after VQSR implementation.

Pharmacogenetic variant analysis

The Stargazer v1.08¹¹ tool was used to call diplotypes, calculate activity scores, and assign genotype-inferred metabolizer phenotypes for seven genes (*CYP1A2*, *CYP2C9*, *CYP2C19*, *CYP2D6*, *CYP3A4*, *CYP3A5*, *CYP2E1*) relevant to clozapine metabolism¹². Stargazer uses whole genome sequencing data to find phased haplotypes comprised of SNPs, small indels, and large structural variants, and then maps these haplotypes to star alleles based on translation tables maintained by the Pharmacogene Variation Consortium¹³. Notably, previous work has shown Stargazer recalled 100% of star alleles present in the Genetic Testing Reference Material Coordination Program's consensus genotypes¹¹. Furthermore, a comparison of Stargazer-predicted diplotypes for the seven target pharmacogenes with the diplotypes generated by the PharmacScan Solution (ThermoFisher, Carlsbad, USA) array in a subset of our sample (n = 22) tested on both platforms found high diplotype (94.8%) and phenotype (98.1%) concordance (Supplementary Table S1).

Prior to analysis, activity scores for the seven target pharmacogenes were corrected for concomitant inhibitors or inducers (Supplementary Table S2) using a method previously described¹⁴. In brief, activity scores for one or more of the seven genes were multiplied by zero if a strong inhibitor of the corresponding enzyme was present. For moderate inhibitors the activity score was multiplied by 0.5 and for inducers the activity score was multiplied by 1.5. In cases where both an inhibitor and inducer of the same enzyme were present, the uncorrected activity score for the corresponding gene

was retained, as consensus on how to correct activity scores in this situation has not been established. The corrected activity scores were then used to assign a corrected metabolizer phenotype for each of the seven target genes. To determine differences in activity scores and metabolizer phenotypes between the cases and controls, we used the Mann-Whitney U and chi-square tests, respectively. P values were corrected for multiple testing using the Benjamini–Hochberg (B–H) step-up procedure¹⁵.

Copy number variant (CNV) analysis

CNVs (variants with length $\geq 1\text{kb}$) were called using the DRAGEN algorithm and self-normalization method. A merged CNV file was created by compiling copy number state and segmentation mean values for all samples. Segmentation mean values were log transformed to construct copy number variable regions (CNVRs). Ten regions where segmentation mean and log transformed segmentation values had conflicting CNV status were excluded (Supplementary Table S3). We used two different tools - CNVRuler¹⁶ and CoNVaQ¹⁷ to construct CNVRs and perform CNVR association analyses. Using CNVRuler, logistic regression was performed using the first two principal components as covariates, and a minor allele frequency threshold of greater than 0.1. CNVRuler performs multiple testing using the B–H step-up procedure¹⁵. CNVR association analysis was also performed using CoNVaQ with permutation (n=4000) testing by swapping phenotype labels. CNVR encompassing genes were retrieved from the UCSC Genome Browser.

Gene burden analysis and functional annotation of candidate genes

We performed burden analysis using rare and deleterious variants, defined based on the minor allele frequency from global databases and combined annotation dependent depletion (CADD) annotation score using ANNOVAR software¹⁸. A variant was considered rare if the maximum allele frequency was less than 0.05 in the 1000 Genomes Project¹⁹, ESP6500²⁰, ExAC²¹, CG46²² or gnomAD databases²³. A deleterious variant was defined by a CADD Phred score greater than 20. We used CADD scores to include functionally important variants from protein-coding and non-coding regions. Variants that met both criteria were extracted using BCFtools (v1.9)²⁴ and burden analysis was performed on these selected variants. Two different methods were used - Combined and Multivariate Collapsing (CMC) and the sequencing kernel association test (SKAT-O), both implemented in RVTESTS²⁵. Permutation analysis (10,000 iterations) was carried out in R by permuting phenotype labels (case and control) of observations (i.e. total allele counts) to derive

empirical p-values. We also used TRAPD (Testing Rare vARiants using Public Data)²⁶ software to compute the frequency of rare and deleterious alleles of prioritised genes using genome data from 15,708 individuals in the gnomAD v2 database (build hg19)²³ and then compared these frequencies with those observed in our cases and controls using a two proportion Z-test. P-values were corrected using the Bonferroni method.

To evaluate the tolerance of genes for functional genetic variation, Residual Variation Intolerance Score (RVIS) scores were fetched using the web-based tool Gene Intolerance²⁷. RVIS scores are used to rank genes in terms of their functional tolerance²⁸. Genes with negative scores represent less tolerance to functional variations. Gene enrichment analysis was performed using ToppFun²⁹. Finally, we assessed the mRNA expression of candidate genes in left ventricular-septal tissue from 21 healthy adult donors using published RNASeq data³⁰. Raw RNASeq data was retrieved from the Zenodo Data repository³¹. Raw read counts were normalized with DESeq2, using the median of ratios method³².

RESULTS

A summary of the study design and key results are shown in Figure 1.

Study participants and sequencing

Participant characteristics and relevant clinical information for the two patient groups are shown in Table 1. Cases and controls did not differ significantly in their demographic or clinical characteristics, with the exception of titration slope. On average, cases received a faster titration than controls ($p = 0.006$). However, *post hoc* comparisons of case and control titration slopes with those recommended in titration protocols used in Canada³³, Australia³⁴, and United Kingdom³⁵ showed that neither case nor control slopes differed from these national recommendations (Figure 2). In addition, *post hoc* examination showed no difference in titration slopes by ancestry (Supplementary Figure S2).

One of the control samples failed initial quality assessment post-sequencing, resulting in 25 cases and 24 controls available for further analysis with an average depth of reads and average read mapping across the samples of 33.65x and 92.9%, respectively (Supplementary Figure S3). Ti/Tv (transition/transversion) ratio for both raw (2.00) and filtered (2.02) calls were in the acceptable whole genome range. On average, there were 3,833,700 SNPs, 953,459 indels and 619 CNVs per individual

(Supplementary Table S4). The final jointly called dataset contained 16,014,407 variants (both SNPs and indels).

Pharmacogenetic variants

Observed diplotype frequencies for the seven targeted pharmacogenes, along with the corresponding uncorrected activity scores and genotype-inferred metabolizer phenotypes among cases and controls, are shown in Supplementary Table S5. No significant differences in uncorrected or corrected activity scores were found between cases and controls (Supplementary Table S6) nor were differences detected in the distribution of genotype-inferred metabolizer phenotypes (Supplementary Table S7). Furthermore, titration slopes were not correlated with activity scores for the seven targeted pharmacogenes in cases or controls (Supplementary Table S8). Importantly, *post hoc* gene burden analysis did not reveal any differences in enrichment of rare and deleterious variants in the seven genes (*CYP1A2*, *CYP2C9*, *CYP2C19*, *CYP2D6*, *CYP3A4*, *CYP3A5*, *CYP2E1*) known to be involved in clozapine metabolism.

Copy number variants

We identified 30,340 CNVs across the 49 samples. Comparing the average number of CNVs between cases and controls revealed no statistically significant differences in losses (cases: mean = 498, $\pm$ standard deviation = 28; controls: 503 $\pm$ 19, $p = 0.42$) or gains (cases: 102 $\pm$ 10 vs. controls: 117 $\pm$ 8, $p = 0.26$) (Supplementary Table S9). We also did not detect significant differences with respect to the average size of the losses (cases: 10.54 $\pm$ 61.6 kb vs. controls: 10.57 $\pm$ 59.5 kb, $p = 0.97$) or gains (cases: mean 141.37 kb, sd = 721.9 kb; controls: mean = 134.01 kb, sd = 533.5 kb, $p = 0.66$) (Supplementary Table S9). The CNVRuler constructed 3,178 copy number variable regions (CNVRs) among which five were found to be significant ($p < 0.01$, Supplementary Table S10), while the CoNVaQ tool resulted in ten significant CNVRs ($p < 0.01$, Supplementary Table S11). However, no CNVR survived permutation analysis or correction for multiple testing.

Rare and deleterious single nucleotide variants

A total of 22,703 rare and deleterious variants from 8,442 genes (out of 22,480 genic regions scanned) met criteria for gene burden analysis. On average, cases and controls had 739 $\pm$ 51, and 735 $\pm$ 52 rare

and deleterious variants per sample, respectively ($p = 0.779$). We identified 114 and 44 genes ($p < 0.05$) using CMC and SKAT-O, respectively and selected 42 common genes for prioritization analysis (Supplementary Figure S4). Out of 42 genes, 15 genes had a rare and deleterious variant in our cohort (Table 2). All genes survive permutation analysis with *MLLT6* as the top candidate ($p = 4.2 \times 10^{-3}$) but no gene survived multiple testing correction. However, compared to the frequencies of rare and deleterious variants in the gnomAD cohort, cases had significantly greater frequencies for seven (*MLLT6*, *CADPS*, *TACC2*, *L3MBTL4*, *NOL8*, *FAM172A*, *AFDN*) of the 15 candidate genes, after Bonferroni correction (Table 2). Frequencies in controls did not differ from those observed in the gnomAD cohort for any of the 15 genes.

Gene intolerance analysis showed *CADPS*, *AFDN*, and *MLLT6* were the most intolerant to rare and deleterious variation, respectively ranking amongst the 2nd, 5th, and 6th percentile of the most intolerant genes. Gene enrichment analysis of the 15 nominally significant genes revealed no significant functional category or pathway. Likewise, gene enrichment analysis including of the 15 nominally significant genes and the four candidate genes from our previous GWAS (i.e., *SIX3*, *EFHC1*, *ADAM7*, *GNAI5*) revealed no significant functional category or pathway. However, all 15 genes, with the exception of *GPR179* and *SLC6A11*, were expressed in left ventricular septal tissue from healthy human adult donors with *TACC2* and *MLLT6* having the highest expression (Figure 3). Among the GWAS candidates, only *SIX3*, *EFHC1*, and *GNAI5* were expressed in left ventricular septal tissue (Supplementary Figure S5).

DISCUSSION

Using a whole-genome sequencing approach, our study sought to identify associations between three different and unexplored classes of DNA variation (pharmacogenetic, CNVs, rare variants) and clozapine-induced myocarditis⁸. Although we did not identify a single robust genetic marker for differentiating cases from controls, we identified 15 novel genes nominally associated with this important and sometimes fatal ADR - which continues to limit the use of clozapine, a highly effective medication for schizophrenia. Among the novel candidate genes identified, 13 were found to be expressed in human myocardium, specifically the ventricular septum, providing biological plausibility of a link between these genes and clozapine-induced myocarditis. Although the mechanisms by which these genes may increase risk for clozapine-induced myocarditis remain unclear and require further study, including replication in a separate patient cohort, the genes identified now represent novel

targets to inform future functional and clinical studies. Such studies may subsequently improve our understanding of the role played by genetic risk of this serious ADR

Our findings add to the list of candidate genes identified in our previous GWAS (*GNAI5*, *ADAM7*, *SIX3*, *EFHC1*) and HLA (*HLA-C*07:01*) studies of clozapine-induced myocarditis⁸ and suggests that the genetic architecture of this serious ADR is complex and likely polygenic. In fact, each of the candidate genes identified to date have low sensitivity and positive predictive value, limiting their clinical utility. This notion aligns with genomic studies of clozapine-induced agranulocytosis, another rare clozapine ADR, that has been associated with variants from several genes with modest sensitivity (range: 11% - 36%)³⁶. This current state of the evidence coupled with low incidence of clozapine-induced myocarditis highlights the need for international collaboration to facilitate the rapid ascertainment of cases that will ultimately provide the statistical power required to unravel its complex genetic etiology. Recognizing this need, we formed the PROCLAIM Consortium in 2017 that currently comprises 15 recruitment sites across four countries (Canada, USA, Australia, Turkey)⁹ and are actively looking for new sites to join the consortium.

Our gene enrichment analysis was inconclusive and *post hoc* exploration of the 15 genes using the published literature showed limited to no associations with phenotypes related to myocarditis, inflammation, or adverse drug reactions with few exceptions (see Supplementary Discussion). However, this is not unsurprising given the lack of previously published genetic studies examining this ADR. One notable exception was neuropeptide Y (NPY), which has a well-established role in modulating cardiac contractility, protein degradation, and proliferation of cardiomyocytes and has been implicated in the pathogenesis of various cardiovascular morbidities (e.g., cardiac hypertrophy, arrhythmias, heart failure)³⁷. Furthermore, clinical associations between *NPY* genetic variation and antipsychotic-induced weight gain have been reported³⁸. Weight gain and related increases in body mass index (BMI) related to antipsychotic treatment could be clinically relevant given the number of antipsychotic trials patients undergo prior to commencing clozapine and previous work showing high BMI increases clozapine-induced myocarditis fatal outcomes^{6, 39}. Notably, BMI did not statistically differ between our cases and controls, although there was a trend ($p = 0.107$, Cohen's $d = 0.42$) toward higher BMIs in cases. Given the paucity of genetic markers for clozapine-induced myocarditis, future investigation of rare genetic variation in *NPY* and the other 14 putative candidate genes should be considered.

Our findings should be interpreted in the context of notable caveats. Since clozapine-induced myocarditis is a relatively rare event - even despite our international consortium - our patient sample size is small and had suboptimal statistical power to detect small-moderate effect sizes. This was partially mitigated by our demographically-matched case-control design and the deployment of an analysis plan appropriate for small sample sizes. Nevertheless, our results are preliminary and will require independent replication before firm conclusions can be drawn. In addition, functional characterization of the identified genes was limited to existing gene expression data derived from healthy adult human left ventricular septal tissue due to the limited biological material and clinical data available from our study participants. Notably, the PROCLAIM Consortium is currently developing a novel *in vitro* model using patient-derived induced pluripotent stem cells differentiated into beating cardiomyocytes to understand how clozapine induces myocardial inflammation and to investigate the impact common and rare genetic variants and/or epigenetic modifications have on cardiomyocyte structure and function when exposed to clozapine.

In summary, our whole-genome sequencing analysis identified 15 genes nominally associated with clozapine-induced myocarditis that provide novel candidates for future studies. With the possible exception of *NPY*, the mechanism by which these genes increase risk for myocarditis is unclear. Although these candidate genes will require independent validation and their roles in the development of clozapine-induced myocarditis remain to be tested, they provide potential insights into the genomic underpinnings and mechanisms by which clozapine induces myocardial inflammation and damage, that may help improve clinical management in the future.

325 **Acknowledgements**

326 The work was supported in part by the University of Calgary Cumming School of Medicine, Alberta
327 Children's Hospital Research Institute, and University of Melbourne Establishment Grant. P.L. is
328 supported by a National Heart Foundation Future Leader Fellowship (102604).
329

330 **Competing Interests**

331 CAB is the founder and a shareholder of Sequence2Script Inc and a member of the Clinical
332 Pharmacogenetics Implementation Consortium (CPIC) and Pharmacogene Variation Consortium
333 (PharmVar). The remaining authors declare that the research was conducted in the absence of any
334 commercial or financial relationships that could be construed as a potential conflict of interest.
335

336 **Author Contributions**

338 CB and CP conceptualized the study. AN and CB conducted the analyses and wrote the first draft of
339 the manuscript. PL, KR, JM, MJ, NT, RS, DC, RS, SG, and CP contributed to subsequent drafts of the
340 manuscript. All authors approved the final manuscript.

References

1. McGorry P, Killackey, E., Lambert, T., Lambert, M., Jackson, H., Codyre, D., James, N., Pantelis, C., Pirkis, J., Jones, P., Durie, M. A., McGrath, J. J., McGlashan, T., Malla, A., Farhall, J., Herman, H. and Hocking, B. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders. *The Australian and New Zealand journal of psychiatry* 2005; **39**(1-2): 1-30.
2. NICE (2014). Psychosis and schizophrenia in adults: treatment and management. .
3. Siskind D, McCartney L, Goldschlager R, Kisely S. Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis. *Br J Psychiatry* 2016; **209**(5): 385-392.
4. Kilian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. *Lancet* 1999; **354**(9193): 1841-1845.
5. Ronaldson KJ, Fitzgerald PB, McNeil JJ. Clozapine-induced myocarditis, a widely overlooked adverse reaction. *Acta Psychiatrica Scandinavica* 2015; **132**(4): 231-240.
6. Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, Wolfe R, McNeil JJ. Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: A case-control study. *Schizophrenia research* 2012; **141**(2-3): 173-178.
7. Youssef DL, Narayanan P, Gill N. Incidence and risk factors for clozapine-induced myocarditis and cardiomyopathy at a regional mental health service in Australia. *Australas Psychiatry* 2016; **24**(2): 176-180.
8. Lacaze P, Ronaldson KJ, Zhang EJ, Alfirevic A, Shah H, Newman L, *et al.* Genetic associations with clozapine-induced myocarditis in patients with schizophrenia. *Transl Psychiatry* 2020; **10**(1): 37.
9. Bousman C, Greenway S, Tarailo-Graovac M, Long Q, Sellmer R, Crockford D, *et al.* The Pharmacogenomics of Clozapine-Induced myocarditis (PROCLAIM) Consortium. . *Neuropsychopharmacology* 2018: S97–S98.
10. Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, McNeil JJ. A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. *Aust Nz J Psychiat* 2011; **45**(6): 458-465.
11. Lee SB, Wheeler MM, Thummel KE, Nickerson DA. Calling Star Alleles With Stargazer in 28 Pharmacogenes With Whole Genome Sequences. *Clin Pharmacol Ther* 2019; **106**(6): 1328-1337.
12. Thorn CF, Müller DJ, Altman RB, Klein TE. PharmGKB summary: clozapine pathway, pharmacokinetics. *Pharmacogenet Genomics* 2018; **28**(9): 214-222.
13. Gaedigk A, Ingelman-Sundberg M, Miller NA, Leeder JS, Whirl-Carrillo M, Klein TE, *et al.* The Pharmacogene Variation (PharmVar) Consortium: Incorporation of the Human Cytochrome P450 (CYP) Allele Nomenclature Database. *Clin Pharmacol Ther* 2018; **103**(3): 399-401.

14. Lesche D, Mostafa S, Everall I, Pantelis C, Bousman CA. Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity. *Pharmacogenomics J* 2020; **20**(2): 192-201.
15. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. *J R Stat Society Series B (Methodol)* 1995; **57**: 289-300.
16. Kim JH, Hu HJ, Yim SH, Bae JS, Kim SY, Chung YJ. CNVRuler: a copy number variation-based case-control association analysis tool. *Bioinformatics* 2012; **28**(13): 1790-1792.
17. Larsen SJ, do Canto LM, Rogatto SR, Baumbach J. CoNVaQ: a web tool for copy number variation-based association studies. *BMC Genomics* 2018; **19**(1): 369.
18. Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. *Nucleic Acids Res* 2010; **38**(16): e164.
19. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, *et al.* A global reference for human genetic variation. *Nature* 2015; **526**(7571): 68-74.
20. Fu W, O'Connor TD, Jun G, Kang HM, Abecasis G, Leal SM, *et al.* Analysis of 6,515 exomes reveals the recent origin of most human protein-coding variants. *Nature* 2013; **493**(7431): 216-220.
21. Karczewski KJ, Weisburd B, Thomas B, Solomonson M, Ruderfer DM, Kavanagh D, *et al.* The ExAC browser: displaying reference data information from over 60 000 exomes. *Nucleic Acids Res* 2017; **45**(D1): D840-D845.
22. Drmanac R, Sparks AB, Callow MJ, Halpern AL, Burns NL, Kermani BG, *et al.* Human genome sequencing using unchained base reads on self-assembling DNA nanoarrays. *Science* 2010; **327**(5961): 78-81.
23. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J, Wang Q, *et al.* The mutational constraint spectrum quantified from variation in 141,456 humans. *Nature* 2020; **581**(7809): 434-443.
24. Li H. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. *Bioinformatics* 2011; **27**(21): 2987-2993.
25. Zhan X, Hu Y, Li B, Abecasis GR, Liu DJ. RVTESTS: an efficient and comprehensive tool for rare variant association analysis using sequence data. *Bioinformatics* 2016; **32**(9): 1423-1426.
26. Guo MH, Plummer L, Chan YM, Hirschhorn JN, Lippincott MF. Burden Testing of Rare Variants Identified through Exome Sequencing via Publicly Available Control Data. *Am J Hum Genet* 2018; **103**(4): 522-534.
27. Petrovski S, Wang Q, Heinzen EL, Allen AS, Goldstein DB. Genic intolerance to functional variation and the interpretation of personal genomes. *PLoS Genet* 2013; **9**(8): e1003709.

436 28. Petrovski S, Gussow AB, Wang Q, Halvorsen M, Han Y, Weir WH, *et al*. The Intolerance of Regulatory
437 Sequence to Genetic Variation Predicts Gene Dosage Sensitivity. *PLoS Genet* 2015; **11**(9): e1005492.
438

439 29. Chen J, Bardes EE, Aronow BJ, Jegga AG. ToppGene Suite for gene list enrichment analysis and
440 candidate gene prioritization. *Nucleic Acids Res* 2009; **37**(Web Server issue): W305-311.
441

442 30. Hahn V, Knutsdottir H, Luo X, Bedi K, Margulies K, Haldar S, *et al*. Myocardial gene expression
443 signatures in human heart failure with preserved ejection fraction. *Zenodo Data Repository* 2020.
444

445 31. Hahn V, Knutsdottir H, Luo X, Bedi K, Margulies K, Haldar S, *et al* (2020). Myocardial gene expression
446 signatures in human heart failure with preserved ejection fraction: Zenodo Data Repository.
447

448 32. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data
449 with DESeq2. *Genome Biol* 2014; **15**(12): 550.
450

451 33. Health Canada (2020). Clozapine Product Monograph. Health Canada: Ottawa.
452

453 34. ACSQHC (2012). National Adult Clozapine Titration Chart User Guide. Australian Commission on Safety
454 and Quality in Health Care Sydney.
455

456 35. NHS (2019). CLOZAPINE TREATMENT GUIDELINES. National Health Service Foundation Trust: United
457 Kingdom.
458

459 36. Legge SE, Walters JT. Genetics of clozapine-associated neutropenia: recent advances, challenges and
460 future perspective. *Pharmacogenomics* 2019; **20**(4): 279-290.
461

462 37. Tan CMJ, Green P, Tapoulal N, Lewandowski AJ, Leeson P, Herring N. The Role of Neuropeptide Y in
463 Cardiovascular Health and Disease. *Front Physiol* 2018; **9**: 1281.
464

465 38. Shams TA, Müller DJ. Antipsychotic induced weight gain: genetics, epigenetics, and biomarkers
466 reviewed. *Curr Psychiatry Rep* 2014; **16**(10): 473.
467

468 39. Ronaldson KJ, Fitzgerald PB, Taylor AJ, Topliss DJ, McNeil JJ. Clinical course and analysis of ten fatal
469 cases of clozapine-induced myocarditis and comparison with 66 surviving cases. *Schizophrenia*
470 *research* 2011; **128**(1-3): 161-165.
471
472
473

Figure Legends

Figure 1. PROCLAIM study design, analysis and key results. Age, sex and ethnicity matched treatment resistant schizophrenia patients who did (cases) or did not (controls) develop myocarditis following clozapine exposure were recruited. Using whole genome sequencing data, candidate pharmacogenetic variants, copy number variable regions and rare variants were examined for their association with clozapine-induced myocarditis.

Figure 2. Distribution of titration slopes by history of clozapine-induced myocarditis. Cases differed significantly from controls ($p = 0.006$). Dashed lines represent titration slopes recommended by clozapine dosing protocols in Canada, United Kingdom, and Australia. Case titration slopes did not differ from slopes recommended by protocols used in Canada ($p = 0.544$, United Kingdom ($p = 0.795$), or Australia ($p = 0.259$). Likewise, control titration slopes did not differ from slopes recommended by protocols used in Canada ($p = 0.187$, United Kingdom ($p = 0.248$), or Australia ($p = 0.869$).

Figure 3. Normalised RNASeq read counts of the 15 nominally associated loci identified in gene burden analysis in left ventricular septal tissue of healthy adult donors ($n=21$). *MLLT6*: PHD Finger Containing, *CADPS*: Calcium Dependent Secretion Activator, *TACC2*: Transforming Acidic Coiled-Coil Containing Protein 2, *L3MBTL4*: L3MBTL Histone Methyl-Lysine Binding Protein 4, *NPY*: Neuropeptide Y, *SLC25A21*: Solute Carrier Family 25 Member 21, *PARVB*: Parvin Beta, *GPR179*: G Protein-Coupled Receptor 179, *ACAD9*: Acyl-CoA Dehydrogenase Family Member 9, *NOL8*: Nucleolar Protein 8, *NADK2*: NAD Kinase 2, Mitochondrial, *FAM172A*: Family With Sequence Similarity 172 Member A, *AFDN*: Afadin, Adherens Junction Formation Factor, *SLC6A11*: Solute Carrier Family 6 Member 11, *PXDN*: Peroxidasin

Table 1. Demographic and clinical characteristics of participants with (N = 25) and without (N = 25) a history of clozapine-induced myocarditis

Characteristic	Clozapine-induced myocarditis	Clozapine-tolerant controls	P
Age, mean (sd) years	36 (13)	35 (11)	0.650
Sex, n (%) males	18 (72%)	19 (76%)	0.747
Self-Report Ancestry ^a , n (%)			0.695
European	21 (84%)	20 (80%)	
East Asian	2 (8%)	3 (12%)	
South Asian	0 (0%)	1 (4%)	
Near Eastern	1 (4%)	1 (4%)	
Oceanian	1 (4%)	0 (0%)	
Body mass index, mean (sd)	31 (10)	27 (9)	0.107
Highest dose received in first 28 days, mean (sd)	274 (84)	310 (150)	0.366
Titration slope ^b , mean (sd)	20 (8)	14 (6)	0.006
Days from clozapine initiation to myocarditis, mean (sd)	15 (5)	—	—
Valproic acid use, n (%)	6 (25%)	8 (32%)	0.588
Concomitantly used inhibitors, n (%)			
CYP1A2 inhibitor ^c	0 (0%)	0 (0%)	1.000
CYP2C9 inhibitor ^c	0 (0%)	0 (0%)	1.000
CYP2C19 inhibitor ^c	2 (8%)	2 (8%)	1.000
CYP2D6 inhibitor ^c	5 (20%)	6 (24%)	0.733
CYP2E1 inhibitor ^c	0 (0%)	0 (0%)	1.000
CYP3A4/5 inhibitor ^c	0 (0%)	0 (0%)	1.000
Concomitantly used inducers, n (%)			
Tobacco (smoked)	6 (26%)	10 (40%)	0.307
Carbamazepine	0 (0%)	1 (4%)	0.312

^a Ancestry groupings are based on the biogeographic grouping system described by Huddart et al., Clin Pharmacol Ther. 2019, 105(5): 1256-1262.

^b Slope = (highest dose in first 28 days - starting dose) / (days of titration - 1). A higher slope translates to a faster titration.

^c Medications taken by participants that are known to be moderate or strong inhibitors of CYP1A2, CYP2C19, CYP2C19, CYP2D6, CYP2E1 or CYP3A4/5 according to the Flockhart Drug Interactions Table (<https://drug-interactions.medicines.uh.edu/Main-Table.aspx>)

				Case vs Control			Two Proportion Z-test		
Genes	Frequency Controls (n=24)	Frequency Cases (n=25)	Frequency gnomAD (n=15,708)	CMC P-value	SKAT-O P-value	Empirical P-value	Case vs gnomAD P-value	Control vs gnomAD P-value	RVIS (Percentile) ¹
MLLT6	0.000	0.140	0.007	0.0051	0.0324	0.0042	3.9x10 ⁻¹⁵ *	0.6818	-1.51 (6.0%)
CADPS	0.000	0.120	0.025	0.0104	0.0207	0.0101	0.0024*	0.4354	-2.30 (2.2%)
TACC2	0.021	0.160	0.024	0.0119	0.0500	0.0103	9.9x10 ⁻⁶ *	0.9203	1.92 (96.5%)
L3MBTL4	0.000	0.100	0.007	0.0208	0.0354	0.0198	3.5x10 ⁻⁸ *	0.6818	0.38 (66.9%)
NPY	0.000	0.100	0.032	0.0208	0.0208	0.0208	0.0539	0.3735	-0.08 (45.5%)
SLC25A21	0.021	0.140	0.037	0.0240	0.0344	0.0209	0.0065	0.6745	0.51 (72.2%)
PARVB	0.000	0.100	0.025	0.0208	0.0445	0.0211	0.0166	0.4354	0.29 (62.8%)
GPR179	0.000	0.100	0.039	0.0208	0.0399	0.0218	0.1158	0.3222	2.80 (98.9%)
ACAD9	0.000	0.100	0.028	0.0208	0.0491	0.0218	0.0295	0.4056	-0.69 (21.3%)
NOL8	0.000	0.100	0.049	0.0208	0.0491	0.0221	0.2382	0.2670	1.92 (96.5%)
NADK2	0.000	0.100	0.015	0.0208	0.0491	0.0222	0.0005*	0.5485	0.30 (63.4%)
FAM172A	0.021	0.140	0.016	0.0240	0.0457	0.0225	9.2x10 ⁻⁷ *	0.8145	-0.38 (32.2%)
AFDN	0.000	0.100	0.017	0.0208	0.0208	0.0227	0.0013*	0.5222	-1.65 (5.0%)
SLC6A11	0.000	0.120	0.029	0.0208	0.0292	0.0239	0.0068	0.3953	-0.71 (20.7%)
PXDN	0.000	0.100	0.009	0.0208	0.0399	0.0253	0.0348	0.6384	-1.08 (11.4%)

507 Comparing frequency of qualifying rare and deleterious variants per gene between cases and controls in the PROCLAIM cohort.
508 Frequencies of the qualifying rare variants in cases and controls were also compared with public controls (gnomAD v2 public
509 database).
510 *significant after Bonferroni correction (0.05/15 tests = 0.0033). 1 = RVIS Score, a gene-based gene intolerance score based on ExAC
511 v2 release. Genes with negative scores are more “intolerant” than those with positive scores. *MLLT6*: PHD Finger Containing,
512 *CADPS*: Calcium Dependent Secretion Activator, *TACC2*: Transforming Acidic Coiled-Coil Containing Protein 2, *L3MBTL4*:
513 L3MBTL Histone Methyl-Lysine Binding Protein 4, *NPY*: Neuropeptide Y, *SLC25A21*: Solute Carrier Family 25 Member 21,
514 *PARVB*: Parvin Beta, *GPR179*: G Protein-Coupled Receptor 179, *ACAD9*: Acyl-CoA Dehydrogenase Family Member 9, *NOL8*:
515 Nucleolar Protein 8, *NADK2*: NAD Kinase 2, Mitochondrial, *FAM172A*: Family With Sequence Similarity 172 Member A, *AFDN*:
516 Afadin, Adherens Junction Formation Factor, *SLC6A11*: Solute Carrier Family 6 Member 11, *PXDN*: Peroxidas

517
518

Clozapine-Induced
Myocarditis
(n = 25)

Clozapine-Tolerant
Controls
(n = 25)

Whole genome Sequencing
(Illumina HiSeq, 100 bp paired, Average depth 30x)

Pharmacogenetic Variants

Metabolizer
phenotypes

No significant results
Tables S5 and S6

Copy Number Variations

Association
analysis

No significant results
Tables S10 and S11

Rare Variants

Gene Burden
Analysis

15 nominally significant
Table 2